Weiss Ratings Reaffirms Sell (D-) Rating for 111 (NASDAQ:YI)

111 (NASDAQ:YI)‘s stock had its “sell (d-)” rating reissued by stock analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

111 Price Performance

Shares of NASDAQ YI opened at $7.50 on Friday. 111 has a 12-month low of $4.15 and a 12-month high of $12.60. The company has a market capitalization of $64.80 million, a PE ratio of -11.72 and a beta of 0.44. The firm’s 50-day moving average is $7.82 and its two-hundred day moving average is $7.52.

111 (NASDAQ:YI) last announced its quarterly earnings results on Thursday, June 19th. The company reported ($0.20) earnings per share (EPS) for the quarter. The business had revenue of $486.35 million for the quarter.

Hedge Funds Weigh In On 111

Hedge funds and other institutional investors have recently modified their holdings of the company. Deuterium Capital Management LLC acquired a new stake in shares of 111 in the first quarter worth $81,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of 111 in the first quarter worth $92,000. JPMorgan Chase & Co. increased its position in shares of 111 by 43,619.9% in the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock worth $191,000 after acquiring an additional 305,339 shares in the last quarter. Napean Trading & Investment Co Singapore PTE Ltd acquired a new stake in shares of 111 in the fourth quarter worth $245,000. Finally, FIL Ltd acquired a new stake in shares of 111 in the fourth quarter worth $450,000. 21.32% of the stock is owned by institutional investors and hedge funds.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.